Loading
Treace Medical Concepts, Inc. Stock: price and insider trades · United States
1 insider bought €211k of shares over the last 90 days, the latest filed 24 Aug 2026.
Treace Medical Concepts, Inc.: what insiders have been doing
Treace Medical Concepts, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 26 filings signed by 6 insiders.
No insider sold shares on the market over the period. Instead, the filings list 4 purchases totalling €291k, made by 1 insider. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 1 chief executive among the declarants. Treace John T. filed the largest purchase, €152k, on 24 August 2026, which represents 0.058% of the company's market value.
With 26 filings in twelve months, the company is more active than the median of 19 filings across the 5,814 companies we follow on the same exchange. The full history, which starts in 2021, counts 30 purchases against 73 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 212.7 m USD and net income of -59.0 m USD.
The last purchase on record was published on 24 August 2026, which is 55 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
231
Thresholds
n/a
Buy Volume
€8M
30 ops. · all time
Sell Volume
€41M
73 ops. · all time
Who traded when
BuySaleJohn T. Treace5 buys
Since the insiders bought
- -14.3%Entry US$4.81 · Close 15 Oct 2026 US$4.12
- +69.2%Entry US$15.90 · Close at T+365 US$26.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,421 of 24,148 companies
23.5
score / 100
Value13
Quality34
FCF yld-11%
Earn yld-22%
EV/EBITDA·
ROE-72%
Gross mgn80%
Net mgn-28%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.12
Analyst consensus
3 analysts2.80/5
US$4.50Target US$5.50(+33%)US$7.00
Income statement
RevenueUS$212.7M
Gross profitUS$169.8M80% margin
EBITDA-US$43.1M-20% margin
Net income-US$59M-29.0% margin
Valuation
PER (forward)-4.8x
P/Book4.0x
Beta1.49
Balance sheet & cash
Market capUS$267.9M
Total debtUS$71.9M
Free Cash Flow-US$29.5M
Debt / Equity108%
Profitability & ownership
ROE-72.0%
ROA-17.3%
% insiders25.2%
% institutions49.3%
Last declaration on 2 October 2026
Declarations231 total
25,457 shares0Common StockSEC:0001193125-26-412727:0
39,944 shares@ US$4.43560.058% mcap1.9% of flowCommon StockSEC:0001193125-26-363737:0
Canonical exit: 18 Nov 2026 (T+90)
5,000 shares@ US$4.34950.0072% mcap0.2% of flowCommon StockSEC:0001193125-26-363737:1
Canonical exit: 19 Nov 2026 (T+90)
11,000 shares@ US$4.33920.016% mcap0.5% of flowCommon StockSEC:0001193125-26-363737:2
Canonical exit: 22 Nov 2026 (T+90)
16,253 shares0Common StockSEC:0001193125-26-347222:0
9,814 shares0Common StockSEC:0001193125-26-347275:0
43,000 shares@ US$2.17390.031% mcap1.0% of flowCommon StockSEC:0001193125-26-224391:0
Canonical exit: 10 Aug 2026 (T+90)
175 shares0Common StockSEC:0001193125-26-102764:0
401 shares0Common StockSEC:0001193125-26-102763:0
2,062 shares0Common StockSEC:0001193125-26-102762:0
16,875 shares@ US$1.056.5% of flowCommon StockSEC:0001193125-26-047313:0
53,500 shares@ US$0.7214.3% of flowCommon StockSEC:0001193125-26-021450:0
150,000 shares0Common StockSEC:0001193125-26-021453:0
9,451 shares0Common StockSEC:0001193125-26-021452:0
14,254 shares0Common StockSEC:0001193125-26-021449:0
4,544 shares0Common StockSEC:0001193125-26-012081:0
13,219 shares0Common StockSEC:0001193125-26-012080:0
20,090 shares0Common StockSEC:0001193125-25-307269:0
208 shares0Common StockSEC:0001193125-25-253801:0
25 of 231 declarations
About Treace Medical Concepts, Inc.
Treace Medical Concepts, Inc. is a U.S.-based medical technology company listed on the NASDAQ in the United States under the ticker TMCI. Headquartered in Ponte Vedra, Florida, Treace focuses on foot and ankle surgery, with a highly specialized franchise in bunion correction and midfoot deformity repair. The company was founded in 2014 and has built its identity around a 3D correction approach designed to address not only the visible bunion deformity, but also the underlying biomechanical instability that drives recurrence.
The company’s core commercial engine is the Lapiplasty® platform, a combination of instruments, implants, and surgical workflow designed to enable reproducible triplanar bunion correction and, in Treace’s positioning, faster return to weight bearing than some traditional procedures. Over time, Treace broadened its portfolio with Adductoplasty®, which targets midfoot adductus deformity and osteoarthritis, as well as minimally invasive or percutaneous offerings such as Nanoplasty®, Percuplasty™, and Micro-Lapiplasty®. It has also expanded its implant and instrumentation ecosystem, including plate systems and procedure-specific trays. This creates a relatively concentrated business model: Treace is not a broad orthopedics company, but a focused innovator in a narrow and clinically defined sub-segment.
Read moreShow less
From a competitive perspective, Treace competes against larger orthopedic and device companies, but its niche positioning is a key differentiator. Its competitive advantages are centered on proprietary technology, surgeon training and education, and a workflow that aims to make complex bunion surgery more standardized, efficient, and reproducible. The company primarily sells to foot and ankle surgeons, ambulatory surgery centers, hospitals, and other specialized care settings. Its commercial footprint is overwhelmingly in the United States, although its clinical messaging and product development are relevant to broader global medtech trends.
Recent developments highlight continued product innovation. Treace has recently announced new product enhancements and, in 2026, reported the first surgical case using Lapiplasty Lightning™ technology. At the same time, recent financial updates through 2024 and 2025 suggest a business that is still investing heavily in innovation and commercial expansion while navigating pressure on profitability and changing growth expectations. For investors, TMCI should be viewed as a specialized U.S. medtech name on the NASDAQ, with a differentiated franchise in bunion and midfoot surgery, meaningful product momentum, and execution risk tied to adoption rates, surgeon conversion, and market acceptance of its next-generation systems.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
